Compass Therapeutics, Inc. CMPX 深 滬
已收盤 02-06 16:00:00 美东时间
6.52
+0.300
+4.82%
華盛通- 最 高6.685
- 今 開6.35
- 成交量 200.81万股
- 最 低 6.29
- 昨 收 6.22
- 總市值 11.60亿
- 52周最高 6.88
- 市盈率 靜 --
- 換手率 1.13%
- 52周最低 1.33
- 委 比 -7.80%
- 總股本 1.78亿
- 歷史最高 6.88
- 量 比 0.81
- 振 幅 6.35%
- 歷史最低 0.765
- 每 手 1
- 風險率 1.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index falling around 0.2% on Wednesd...
01-07 23:03
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
D. Boral Capital Maintains Buy on Compass Therapeutics, Maintains $30 Price Target
D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and maintains $30 price target.
01-06 22:39
Compass Therapeutics Provides Corporate Update
Compass Therapeutics provided updates on its pipeline, including tovecimig's Phase 2/3 study in biliary tract cancer with PFS and OS analyses expected in late Q1 2026. CTX-8371 showed durable responses in Hodgkin lymphoma and triple negative breast cancer, with cohort expansions underway. CTX-10726's Phase 1 study is set to begin in Q1 2026. The company expanded its leadership team with the appointment of Arjun Prasad as Chief Commercial Officer ...
01-06 13:00
Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care
William Blair starts coverage on Compass Therapeutics, saying its lead drug could reshape bile duct cancer treatment and reach over $1 billion in global sales.
01-06 02:06
William Blair Initiates Coverage On Compass Therapeutics with Outperform Rating
William Blair analyst Matt Phipps initiates coverage on Compass Therapeutics (NASDAQ:CMPX) with a Outperform rating.
01-05 21:44
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Therapeutics granted stock options to its new Chief Commercial Officer, Arjun Prasad, and Chief Medical Officer, Cynthia Sirard, under its 2025 Inducement Plan. Each received options to purchase 1,000,000 shares at $5.17 per share, vesting over four years. The grants were approved by the Compensation Committee as material inducements to employment. Compass Therapeutics focuses on developing antibody-based therapeutics to treat cancers by ...
01-05 21:30
Compass Therapeutics Announces Key Leadership Appointments
Compass Therapeutics has appointed Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, effective January 1, 2026. With decades of experience in oncology product launches and clinical development, they bring expertise in advancing therapies for biliary tract cancer and other oncology indications. Prasad, previously at Servier and Agios, has successfully launched multiple oncology products, including ...
01-05 13:00
Compass Therapeutics Files For Up To $400M Mixed Shelf Offering
Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may from time to time issue, in one or more series or classes, up to $400,000,000 in aggregate principal amount of our common stock, preferred stock, warrants
2025-12-31 05:07
2026美股生物科技板块怎么投资？杰富瑞：关注6大首选、7大潜力和5大并购目标
杰富瑞近日发布了关于 2026 年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
2025-12-25 15:40
